Aurobindo Pharma Unit Gets USFDA Nod for Everolimus Tablets; $78M Market Awaits

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAkshat Lakshkar|Published at:
Aurobindo Pharma Unit Gets USFDA Nod for Everolimus Tablets; $78M Market Awaits
Overview

Aurobindo Pharma's subsidiary, Eugia Pharma Specialities Limited, secured final USFDA approval for Everolimus Tablets. This expands the company's oncology and specialty product portfolio, targeting a US market estimated at $78 million annually. The approval marks Eugia's 184th ANDA approval, reinforcing its manufacturing capabilities in regulated markets.

Aurobindo Pharma Subsidiary Eugia Pharma Secures USFDA Approval for Everolimus Tablets

February 26, 2026: Aurobindo Pharma's subsidiary, Eugia Pharma Specialities Limited, received final USFDA approval for Everolimus Tablets.
The drug is bioequivalent to Novartis' Zortress Tablets and targets an estimated US$ 78 million market.

Reader Takeaway: USFDA nod for Everolimus Tablets boosts portfolio; competitive generics market remains a challenge.

What just happened (today’s filing)

Aurobindo Pharma announced that its wholly-owned subsidiary, Eugia Pharma Specialities Limited, has received final approval from the US Food and Drug Administration (USFDA).

The approval grants permission for the manufacture and marketing of Everolimus Tablets in various strengths.

These tablets are confirmed to be bioequivalent and therapeutically equivalent to Novartis' Zortress Tablets.

The company anticipates launching the product in the first quarter of fiscal year 2027 (Q1FY27). The estimated market size for Everolimus Tablets in the US was US$ 78 million for the twelve months ending December 2025.

This marks the 184th Abbreviated New Drug Application (ANDA) approval for Eugia Pharma Specialities Group facilities.

Why this matters

This USFDA approval is set to expand Aurobindo Pharma's existing product portfolio by adding a new generic drug.

It specifically reinforces Eugia Pharma's established capabilities in manufacturing complex oncology and sterile specialty products.

Securing approval for a product in a significant market like the US validates the subsidiary's compliance with stringent regulatory standards.

The backstory (grounded)

Eugia Pharma Specialities Limited has a strong history of obtaining USFDA approvals, with this latest one being its 184th ANDA approval from the group's facilities.

Previously, Eugia has secured USFDA nods for other significant oncology drugs, including Dasatinib Tablets and Pazopanib Tablets, demonstrating its focus on this therapeutic area.

Aurobindo Pharma itself is a major player in the pharmaceutical industry, with numerous USFDA-approved facilities and a broad portfolio covering oncology, cardiovascular, and CNS segments, among others.

What changes now

  • Product Portfolio Expansion: Aurobindo Pharma adds a new generic drug, Everolimus Tablets, to its US market offerings.
  • Market Access: The approval grants access to the US market for Everolimus Tablets, targeting a segment with an estimated value of US$78 million.
  • Subsidiary Strength: It further solidifies Eugia Pharma's position as a key manufacturer of specialty and oncology generics for regulated markets.
  • Revenue Potential: The launch in Q1FY27 offers a new potential revenue stream for the company.

Risks to watch

The company's own disclaimer highlights that actual developments and results could differ materially from expectations due to various risks and uncertainties.

In February 2025, Aurobindo Pharma faced a significant GST demand and penalty of over ₹155 crore.

Previously, in 2019, SEBI imposed a penalty of approximately ₹22.6 crore on Aurobindo Pharma and its promoters for insider trading violations.

Peer comparison

Several Indian pharmaceutical companies are actively expanding their footprint in the lucrative US generics market, particularly in oncology.

Competitors like Sun Pharmaceutical Industries, Cipla, Dr. Reddy's Laboratories, and Zydus Lifesciences also hold USFDA approvals for various products, including cancer drugs, and have substantial ANDA filings.

Context metrics (time-bound)

  • The estimated market size for Everolimus Tablets in the US is US$ 78 million for the twelve months ending December 2025.
  • This approval represents the 184th ANDA received by Eugia Pharma Specialities Group facilities.

What to track next

  • Monitor the actual launch timeline and commencement of sales for Everolimus Tablets in Q1FY27.
  • Observe the market uptake and sales performance against the estimated market size.
  • Track any further product approvals or pipeline developments from Eugia Pharma Specialities.
  • Keep an eye on the company's overall financial performance and its ability to navigate regulatory and competitive landscapes.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.